ADMA Biologics Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Global X Robo Global Robotics & Automation ETF trades at $84.61. The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ROBO | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $90.34 |
52-Week Low | $7.60 | $62.34 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
ROBO trades at $84.50, up 1.25% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights robotics stocks rallying, with thematic ETF interest growing in AI and automation. The stock shows strong momentum but lacks disclosed financial ratios, requiring deeper fundamental verification.
Outlook is cautiously optimistic due to sector tailwinds from AI infrastructure growth, but risks include cyclical exposure and high valuations. Investors should assess upcoming earnings for profitability metrics, as current data gaps limit fundamental clarity amid positive market sentiment.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →